Christopher D. Turner

7.1k total citations · 1 hit paper
67 papers, 2.5k citations indexed

About

Christopher D. Turner is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Christopher D. Turner has authored 67 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Genetics, 22 papers in Pulmonary and Respiratory Medicine and 18 papers in Molecular Biology. Recurrent topics in Christopher D. Turner's work include Glioma Diagnosis and Treatment (15 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Christopher D. Turner is often cited by papers focused on Glioma Diagnosis and Treatment (15 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Christopher D. Turner collaborates with scholars based in United States, United Kingdom and France. Christopher D. Turner's co-authors include Anthony H.V. Schapira, Christine Chordas, Narayana I. Narasimhan, Jonathan M. Cooper, Celiane Rey‐Casserly, Cori Liptak, Victor M. Rivera, Frank G. Haluska, Jörge E. Cortes and Moshe Talpaz and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Christopher D. Turner

65 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

2012 527 citations Jörge E. Cortes, Hagop M. Kantarjian et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher D. Turner United States	25	837	777	628	513	501	67	2.5k
John Camoriano United States	27	946 1.1×	714 0.9×	735 1.2×	880 1.7×	332 0.7×	66	2.5k
Cornelius F. Waller Germany	31	612 0.7×	867 1.1×	623 1.0×	1.0k 2.0×	419 0.8×	158	3.2k
Pascal Chastagner France	34	1.1k 1.3×	1.1k 1.4×	341 0.5×	634 1.2×	513 1.0×	161	3.5k
Adam J. Olszewski United States	28	781 0.9×	539 0.7×	193 0.3×	1.3k 2.6×	246 0.5×	212	3.1k
Casilda Balmaceda United States	26	947 1.1×	396 0.5×	220 0.4×	846 1.6×	431 0.9×	51	2.4k
Michael C. Frühwald Germany	35	491 0.6×	2.6k 3.3×	316 0.5×	301 0.6×	364 0.7×	183	4.0k
Anita D’Souza United States	28	321 0.4×	903 1.2×	1.3k 2.1×	1.1k 2.1×	108 0.2×	217	2.6k
Antonio Silvani Italy	28	1.5k 1.8×	944 1.2×	115 0.2×	931 1.8×	765 1.5×	182	3.3k
Taxiarchis Kourelis United States	28	612 0.7×	1.7k 2.2×	1.1k 1.7×	813 1.6×	87 0.2×	215	2.7k
Dominique Chauveau France	39	258 0.3×	2.3k 3.0×	190 0.3×	338 0.7×	1.2k 2.3×	160	5.1k

Countries citing papers authored by Christopher D. Turner

Since Specialization

Citations

This map shows the geographic impact of Christopher D. Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher D. Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher D. Turner more than expected).

Fields of papers citing papers by Christopher D. Turner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher D. Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher D. Turner. The network helps show where Christopher D. Turner may publish in the future.

Co-authorship network of co-authors of Christopher D. Turner

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher D. Turner. A scholar is included among the top collaborators of Christopher D. Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher D. Turner. Christopher D. Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Turner, Christopher D.. (2024). Diabetes mellitus and periodontal disease: some perspectives in care. A Review. 3. 206–206.

Gainor, Justin F., Giuseppe Curigliano, D.-W. Kim, et al.. (2021). MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 16(1). S31–S32. 2 indexed citations

Matthews, Emma, Robert D. S. Pitceathly, Michael G. Hanna, et al.. (2021). Long-term Safety and Efficacy of Mexiletine in Myotonic Dystrophy Types 1 and 2. Neurology Clinical Practice. 11(5). e682–e685. 5 indexed citations

Gainor, Justin F., Giuseppe Curigliano, Robert C. Doebele, et al.. (2021). OA05.02 Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study. Journal of Thoracic Oncology. 16(1). S5–S5. 16 indexed citations

Keam, Bhumsuk, Lori J. Wirth, Aaron S. Mansfield, et al.. (2020). 442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Annals of Oncology. 31. S1413–S1414. 1 indexed citations

Hu, Mimi I., Vivek Subbiah, Lori J. Wirth, et al.. (2020). 1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Annals of Oncology. 31. S1084–S1084. 25 indexed citations

Narasimhan, Narayana I., et al.. (2014). Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects. Cancer Chemotherapy and Pharmacology. 74(2). 341–348. 12 indexed citations

Narasimhan, Narayana I., et al.. (2014). Evaluation of the Effect of Multiple Doses of Lansoprazole on the Pharmacokinetics and Safety of Ponatinib in Healthy Subjects. Clinical Drug Investigation. 34(10). 723–729. 15 indexed citations

Sonnichsen, Daryl, David J. Dorer, Jörge E. Cortes, et al.. (2013). Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemotherapy and Pharmacology. 71(6). 1599–1607. 21 indexed citations

10.

Mauro, Michael J., Jörge E. Cortes, Hagop M. Kantarjian, et al.. (2013). Safety and durability of ponatinib in patients with Philadelphia chromosome-positive (Ph+) leukemia: Long-term follow-up of an ongoing phase I study.. Journal of Clinical Oncology. 31(15_suppl). 7063–7063. 3 indexed citations

11.

Cortes, Jörge E., Hagop M. Kantarjian, Neil P. Shah, et al.. (2012). Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias. New England Journal of Medicine. 367(22). 2075–2088. 527 indexed citations breakdown →

12.

Turner, Christopher D. & Anthony H.V. Schapira. (2010). Mitochondrial matters of the brain: the role in Huntington’s disease. Journal of Bioenergetics and Biomembranes. 42(3). 193–198. 36 indexed citations

13.

Manley, Peter, Xiaochun Li, Christopher D. Turner, et al.. (2009). A prospective, blinded analysis of A‐PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. Pediatric Blood & Cancer. 53(3). 343–347. 2 indexed citations

14.

Turner, Christopher D., Celiane Rey‐Casserly, Cori Liptak, & Christine Chordas. (2009). Late Effects of Therapy for Pediatric Brain Tumor Survivors. Journal of Child Neurology. 24(11). 1455–1463. 138 indexed citations

15.

Gilheeney, Stephen W., Ali Saad, Susan Chi, et al.. (2008). Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. Journal of Neuro-Oncology. 89(1). 89–95. 34 indexed citations

16.

Saad, Ali G., Jessica Sachs, Christopher D. Turner, et al.. (2007). Extracranial Metastases of Glioblastoma in a Child. Journal of Pediatric Hematology/Oncology. 29(3). 190–194. 34 indexed citations

17.

Turner, Christopher D., Jonathan M. Cooper, & Anthony H.V. Schapira. (2007). Clinical correlates of mitochondrial function in Huntington's disease muscle. Movement Disorders. 22(12). 1715–1721. 74 indexed citations

18.

Turner, Christopher D., Susan Chi, Karen J. Marcus, et al.. (2006). Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. Journal of Neuro-Oncology. 82(1). 95–101. 50 indexed citations

19.

Hart, Paul, Raffaele Lodi, B. Rajagopalan, et al.. (2005). Antioxidant Treatment of Patients With Friedreich Ataxia. Archives of Neurology. 62(4). 621–621. 163 indexed citations

20.

Turner, Christopher D., Christopher R. Shea, & Philip M. Rosoff. (2001). Basal Cell Carcinoma Originating From a Nevus Sebaceus on the Scalp of a 7-Year-Old Boy. The American journal of pediatric hematology/oncology. 23(4). 247–249. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact